Systemic lupus erythematosus: prevalence, complications and diagnostic tests
DOI:
https://doi.org/10.62305/biosana.v4i4.238Keywords:
autoimmune disease; diagnostic tests; prevalence of lupus; complicationsAbstract
Systemic lupus erythematosus is an autoimmune disease of unknown cause, characterized by an alteration of the immune response and consequent production of autoantibodies directed at cellular antigens. The Ecuadorian Ministry of Public Health indicates that this disease is more prevalent in women in a 10:1 ratio compared to men. The objective of the research was to determine the prevalence, complications and diagnosis of systemic lupus erythematosus. The methodology used was a bibliographic review, of a descriptive type and documentary design, in which the MeSH and Boolean terms were used. The results highlight that the average prevalence of systemic lupus erythematosus is 55.80%. The most common complications are strokes, preeclampsia, preterm pregnancy and premature birth. Regarding diagnostic tests, they are performed by ELISA and PCR. This leads to the conclusion that cases of lupus are relatively high, especially in women, making complications more common during pregnancy.
Downloads
References
González D, Mejía S, Cruz M. Lupus eritematoso sistémico: enfoque general de la enfermedad. Revista Médica Sinergia. 2021; 6(1).
Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatology and Therapy. 2020; 7: p. 433–446.
Ministerio de Salud Pública. Lupus Eritematoso Sistémico (LES). Guía de Práctica Clínica. Guía práctica. Quito: Ministerio de Salud Pública, Dirección Nacional de Normatización-MSP; 2013.
Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Rheumatic Diseases. 2021; 82(3).
Vásconez-González E, Belén-López M, Cuchiparte D, Peláez K, Cano-Cevallos L, Ortiz-Prado E, et al. Manifestaciones Neurológicas Del Lupus Eritematoso Sistémico: Revisión De Literatura. Rev Ecuat Neurol. 2021; 30(2).
Alghareeb R, Hussain A, Maheshwari M, Khalid N, Patel P. Cardiovascular Complications in Systemic Lupus Erythematosus. Cureus. 2022; 14(7): p. e26671. doi: 10.7759/cureus.26671.
Carballé D, Martpinez E, Mesa L, Espinosa R, Pérez N, Morales M. Complicaciones materno-fetales en gestantes con lupus eritematoso sistémico. Acta méd centro. 2023; 17(2).
Serpa J, Moncayo C, Moncayo D, Idrovo C. upus eritematoso sistémico, manifestaciones clínicas, diagnóstico y tratamiento. Anatomia digital. 2021; 4(1): p. 244-261.
Sánchez J, Ospino M, Salas J, Morales J. Lupus Eritematoso Sistémico: generalidades sobre su fisiopatología, clínica, abordaje diagnóstico y terapéutico. Rev. parag. reumatol. 2023; 9(1).
Cotpes R, Pego-Reigosa J, Seoane-Mato D, Morcillo M, Palma D, Moreno M, et al. Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Rheumatology. 2020; 59(9): p. 2556–2562. doi: https://doi.org/10.1093/rheumatology/kez668.
Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim HY, et al. Trend of prevalence and incidence of systemic lupus erythematosus in South Korea, 2005 to 2015: a nationwide population-based study. Korean J Intern Med. 2020; 35(3): p. 652–661. doi: 10.3904/kjim.2018.303.
Li X, Xiang X, Sun J, Liu S, Liu Y, Feng L, et al. Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study. Modern Rheumatology. 2020; 30(2): p. 21–326. doi: https://doi.org/10.1080/14397595.2019.1589912.
Schwarting A, Friedel H, Garal-Pantaler E, Pignot M, Wang X, Nab H, et al. The Burden of Systemic Lupus Erythematosus in Germany: Incidence, Prevalence, and Healthcare Resource Utilization. Rheumatology and Therapy. 2021; 8: p. 375–393.
Chung MK, Park JS, Lim HS, Lee CH, Lee JS. Incidence and prevalence of systemic lupus erythematosus among Korean women in childbearing years: A nationwide population-based study. Lupus. 20221; 30(4): p. 674 - 679.
Basurto-Pérez M, Ramírez-Galindo M, Carbonell-Montes L. Lupus bulloso como debut de lupus eritematoso sistémico. Reporte de caso. Rev Educ Investig Emer. 2021; 4(1): p. 74-77.
Izmirly P, Ferucci E, Somers E, Wang L, Lim S, Drenkard C, et al. Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Lupus Science&Medicine. 2021; 8(1).
Valenzuela-Almada M, Hocaoglu M, Dabit J, Osei-Onomah SA, Basiaga M, Orandi A, et al. Epidemiology of Childhood-Onset Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Care & Research. 2021; 74(5): p. 728-732. doi: https://doi.org/10.1002/acr.24827.
Grabich S, Farrelly E, Ortmann R, Pollack M, Sze-Jung S. Real-world burden of systemic lupus erythematosus in the USA: a comparative cohort study from the Medical Expenditure Panel Survey (MEPS) 2016–2018. Lupus Science&Medicine. 2022; 9(1).
Borbón M, Rivera F. Manifestaciones Clínicas de Lupus Eritematoso Sistémico en pacientes que acuden con un especialista en el periodo marzo 2007 a febrero 2024. Revista Científica De Salud Y Desarrollo Humano. 2024; 5(3): p. 323–349. doi: https://doi.org/10.61368/r.s.d.h.v5i3.261.
Guraieb-Chahín P, Cantú-Bito C, Soto-Mota A, Guerrero-Torres L, Flores-Silva F, Chiquete E, et al. Stroke in systemic lupus erythematosus: epidemiology, mechanism, and long-term outcome. Lupus. 2020; 29(5).
Myrto K, Dionysis N, Ioannis P, George B. Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. Current Vascular Pharmacology. 2020; 18(6): p. 549-565(17). doi: https://doi.org/10.2174/1570161118666191227101636.
Mukwikwi ER, Pineau C, Vinet E, Clarke A, Nashi E, Kalache F, et al. Retinal Complications in Patients with Systemic Lupus Erythematosus Treated with Antimalarial Drugs. The Journal of Rheumatology. 2020; 47(4): p. 553-556. doi: 10.3899/jrheum.181102.
McVeigh E, Batool A, Stromberg A, Abdel-Latif A, Kazzaz N. Cardiovascular complications of systemic lupus erythematosus: impact of risk factors and therapeutic efficacy—a tertiary centre experience in an Appalachian state. Lupus Science&Medicine. 2021; 8(1).
Wang G, Zhou N, Tian F, Li J, Wen Z. Two complications in patients with systemic lupus erythematosus: lupus cystitis and lupus enteritis. Arch Med Sci. 2022; 18(3): p. 822–824. doi: 10.5114/aoms/146547.
Liu Y, Yu X, Zhang W, Zhang X, Wang M, Ji F. Mechanistic insight into premature atherosclerosis and cardiovascular complications in systemic lupus erythematosus. Journal of Autoimmunity. 2022; 132: p. 102863. doi: https://doi.org/10.1016/j.jaut.2022.102863.
Tan Y, Yang S, Liu Q, Li Z, Mu R, Qiao J, et al. Pregnancy-related complications in systemic lupus erythematosus. Journal of Autoimmunity. 2022; 132: p. 102864. doi: https://doi.org/10.1016/j.jaut.2022.102864.
Ahmed N, Shehata M, Hussein E, Amin D. Complications of Pregnancy in Systemic Lupus Erythematosus Patients. The Medical Journal of Cairo University. 2022; 90(6): p. 843-847. doi: 10.21608/mjcu.2022.253186.
Zambrano-Salguero K, Belalcázar-Sánchez Y. Complicaciones materno- fetales en mujeres gestantes con lupus eritematoso sistémico. MQRInvestigar. 2023; 7(3): p. 379–401. doi: https://doi.org/10.56048/MQR20225.7.3.2023.379-401.
Cabrera A, de Souza D, Souza L, Deleon B, Pagnonceli A. Lupus Eritematoso Sistémico (LES). Estudio de caso y posibles complicaciones. Epicentro Ciencias Salud. 2023; 3(5).
Ling H, Xu SZ, Leng RX, Wu J, Pan HF, Fan YG, et al. Discovery of new serum biomarker panels for systemic lupus erythematosus diagnosis. Rheumatology. 2020; 59(6): p. 1416–1425. doi: https://doi.org/10.1093/rheumatology/kez634.
Zhang B, Liu L, Zhou T, Shi X, Wu H, Xiang Z, et al. A simple and highly efficient method of IFI44L methylation detection for the diagnosis of systemic lupus erythematosus. Clinical Immunology. 2020; 221: p. 108612. doi: https://doi.org/10.1016/j.clim.2020.108612.
Mendes E, Scheinberg M, de Souza V, Machado R, Feijo V, McElwee E, et al. The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations. Lupus. 2021; 30(10).
Ramírez L, Gallo C, Godoy M, Pacheco D. Lupus Eritematoso Sistémico y Manifestaciones en el Sistema Nervioso Central: Un desafío diagnóstico permanente. Casos Clínicos. Rev chil reumatol. 2021; 37(1): p. 34-38.
Yu H, Nagafuchi Y, Fujio K. Clinical and Immunological Biomarkers for Systemic Lupus Erythematosus. Biomolecules. 2021; 11(7): p. 928. doi: https://doi.org/10.3390/biom11070928.
Nashi R, Shmerling R. Antinuclear Antibody Testing for the Diagnosis of Systemic Lupus Erythematosus. Rheumatic Diseases Clinics of North America. 2022; 48(2): p. 569-578. doi: https://doi.org/10.1016/j.rdc.2022.02.012.
Infantino M, Nagy E, Bizzaro N, Fischer K, Bossuyt X, Damoiseaux J. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus. Journal of Translational Autoimmunity. 2022; 5: p. 100139. doi: https://doi.org/10.1016/j.jtauto.2021.100139.
Zhong Y, Zhang W, Hong X, Zeng Z, Chen Y, Liao S, et al. Screening Biomarkers for Systemic Lupus Erythematosus Based on Machine Learning and Exploring Their Expression Correlations With the Ratios of Various Immune Cells. Front. Immunol. 2022; 13.
Emerson J, Gruenewald S, Gomes L, Lin MW, Swaminathan S. The conundrum of neuropsychiatric systemic lupus erythematosus: Current and novel approaches to diagnosis. Front. Neurol. 2023; 14.
Lazar S, Kahlenberg M. Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. Annual Review of Medicine. 2023; 74.
Lino-Peñafiel E, Giler-Zambrano X, Castro-Jalca J. Prevalencia y diagnóstico de laboratorio para lupus eritematoso sistémico en mujeres adultas. Journal ScientificMQRInvestigar. 2023; 7(3).
Al-Adhoubi N, Balushi F, Salmi A, Alí M, Lawati T, Lawati B, et al. A multicenter longitudinal study of the prevalence and mortality rate of systemic lupus erythematosus patients in Oman: Oman Lupus Study. International Journal of Rheumatic Diseases. 2021; 24(6): p. 847-854. doi: https://doi.org/10.1111/1756-185X.14130.
García L, Gobbi C, Quintana R, Alba P, Roverano S, Álvarez A, et al. Frecuencia de eventos cardiovasculares en pacientes con lupus eritematoso sistémico.Datos del registro RELESSAR transversal. Rev. argent. reumatolg. 2023; 34(2).
Yue R, Gurung I, Long X, Xian J, Peng X. Prevalence, involved domains, and predictor of cognitive dysfunction in systemic lupus erythematosus. Lupus. 2020; 29(13).
Laurynenka V, Ding L, Kaufman K, James J, Harley J. A High Prevalence of Anti-EBNA1 Heteroantibodies in Systemic Lupus Erythematosus (SLE) Supports Anti-EBNA1 as an Origin for SLE Autoantibodies. Front. Immunol. 2022; 13.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 BIOSANA Health Scientific Journal. ISSN 2960-8481
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
